244.40
0.41 (0.17%)
| Penutupan Terdahulu | 243.99 |
| Buka | 242.70 |
| Jumlah Dagangan | 41,166 |
| Purata Dagangan (3B) | 768,953 |
| Modal Pasaran | 31,522,955,264 |
| Harga / Jualan (P/S) | 14.77 |
| Harga / Buku (P/B) | 972.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | -15.86% |
| Margin Operasi (TTM) | -15.35% |
| EPS Cair (TTM) | -2.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -33.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8,426.14% |
| Nisbah Semasa (MRQ) | 2.75 |
| Aliran Tunai Operasi (OCF TTM) | 56.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 309.57 M |
| Pulangan Atas Aset (ROA TTM) | -2.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alnylam Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.20 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.43% |
| % Dimiliki oleh Institusi | 98.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 400.00 (HC Wainwright & Co., 63.67%) | Beli |
| Median | 312.00 (27.66%) | |
| Rendah | 220.00 (Cantor Fitzgerald, -9.98%) | Pegang |
| Purata | 320.17 (31.00%) | |
| Jumlah | 11 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 270.13 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Nov 2024 | 400.00 (63.67%) | Beli | 232.27 |
| 04 Nov 2024 | 400.00 (63.67%) | Beli | 269.95 | |
| Piper Sandler | 18 Nov 2024 | 296.00 (21.11%) | Beli | 232.27 |
| Barclays | 01 Nov 2024 | 329.00 (34.62%) | Beli | 273.91 |
| Canaccord Genuity | 01 Nov 2024 | 384.00 (57.12%) | Beli | 273.91 |
| Chardan Capital | 01 Nov 2024 | 300.00 (22.75%) | Beli | 273.91 |
| 11 Oct 2024 | 300.00 (22.75%) | Beli | 284.32 | |
| Needham | 01 Nov 2024 | 320.00 (30.93%) | Beli | 273.91 |
| 10 Oct 2024 | 320.00 (30.93%) | Beli | 278.62 | |
| RBC Capital | 01 Nov 2024 | 300.00 (22.75%) | Beli | 273.91 |
| 10 Oct 2024 | 300.00 (22.75%) | Beli | 278.62 | |
| Raymond James | 01 Nov 2024 | 298.00 (21.93%) | Beli | 273.91 |
| Scotiabank | 01 Nov 2024 | 310.00 (26.84%) | Beli | 273.91 |
| 16 Oct 2024 | 305.00 (24.80%) | Beli | 300.55 | |
| TD Cowen | 21 Oct 2024 | 371.00 (51.80%) | Beli | 292.01 |
| B of A Securities | 14 Oct 2024 | 314.00 (28.48%) | Beli | 283.32 |
| Cantor Fitzgerald | 11 Oct 2024 | 220.00 (-9.98%) | Pegang | 284.32 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GARG PUSHKAL | - | 245.26 | -1,752 | -429,696 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,752 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -429,696 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 245.26 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GARG PUSHKAL | Pegawai | 12 Dec 2024 | Jual automatik (-) | 1,752 | 245.26 | 429,696 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |